Coronavirus Update: No Sign Of Agreement In EU's Bitter Row With AstraZeneca Over Vaccine Supplies
Plus: GSK and Vir Team Up With Lilly On Antibody Combination
The dispute over a likely 60% reduction in supplies of AstraZeneca's COVID-19 vaccine shows no sign of resolution. Meanwhile, Lilly, Vir/GSK team up on COVID-19 antibody combination and Moderna negotiates sale of 100 million additional vaccine doses to US.
You may also be interested in...
In the latest example of cross-industry collaboration in these turbulent times, Novartis is joining forces with Pfizer and BioNTech to help produce their in-demand mRNA vaccine at a facility in Switzerland.
AZ and the EU are at loggerheads over supplies of the COVID-19 vaccine. On top of that, its marketing authorization will present dilemmas.
The bamlanivimab/etesevimab combo, filed for US emergency authorization in November, shows ability to reduce risk of hospitalization or death in COVID-19 patients. Lilly also sees prevention role for bamlanivimab.